(R)-Elagolix , ≥98% , 834153-87-6

CAS NO.：834153-87-6

Empirical Formula: C32H30F5N3O5

Molecular Weight: 631.59

MDL number: MFCD11973645

PRODUCT Properties

• Boiling point: 728.6±70.0 °C(Predicted)
• Density: 1.350
• storage temp.: Store at -20°C
• solubility: DMSO : ≥ 100 mg/mL (158.33 mM)
• pka: 4.40±0.10(Predicted)
• form: Solid
• color: White to off-white
• InChIKey: HEAUOKZIVMZVQL-VWLOTQADSA-N
• SMILES: C(O)(=O)CCCN[C@H](C1=CC=CC=C1)CN1C(=O)N(CC2=C(C(F)(F)F)C=CC=C2F)C(C)=C(C2=CC=CC(OC)=C2F)C1=O

Description and Uses

Elagolix is a gonadotropin-releasing hormone(GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis. Elagolix is an orally administered,nonpeptide small molecule gonadotropin-releasing hormone(GnRH) receptor antagonist that inhibits endogenousGnRH signaling by binding competitively to GnRH receptors in the pituitary gland.
Elagolix results in dose-dependent suppression of luteinizing hormone(LH) and follicle-stimulating hormone(FSH) leading to decreased blood leveis of the ovarian sex hormones, estradiol and progesterone.Elagolix causes a dose-dependent decrease in bone mineral density (BMD).BMD loss is greater with increasing duration of use and may not be completely reversible after stopping treatment.
As milk production is dependent on at least minimal levels of estrogen, this product may reduce milk production.

Elagolix has a potential role for treating uterine bleeding associated to uterine myomas. Elagolix is also used in the methods for treatment of estrogen-dependent disorders including gonadotropin-releasing hormone (GnRH) antagonists in combination with add-back therapy.

Safety

• Symbol(GHS): GHS08
• Signal word: Danger
• Hazard statements: H360
• Precautionary statements: P201-P202-P280-P308+P313-P405-P501